UB Paderborn / Katalog / Suche / in CDI

Epidemiology of transthyretin amyloid cardiomyopathy (ATTR-CM) in France, a study based on the systeme national des donnees de sante (SNDS) the French nationwide claims database

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

HPR122 Cost-Based vs Value-Based - How Do Japan's and Germany's Pricing Frameworks Compare?

Value in health, 2022-12, Vol.25 (12), p.S254-S254

2022

Volltextzugriff (PDF)

HPR161 A Long-Term Forecast of the Economic Impact of Gene Therapies in France

Value in health, 2022-12, Vol.25 (12), p.S262-S262

2022

Volltextzugriff (PDF)

RWD98 Health Care Resource Use and Costs of Hemophilia A in France

Value in health, 2023-12, Vol.26 (12), p.S522-S523

2023

Volltextzugriff (PDF)

EE565 Healthcare Consumption and Costs of Hemophilia B in France

Value in health, 2023-12, Vol.26 (12), p.S161

2023

Volltextzugriff (PDF)

EPH233 Estimation of the Epidemiological and Economic Burden of RSV and Influenza Infection in the Hospital Setting Among Adults 65 Years and Older in France

Value in health, 2023-12, Vol.26 (12), p.S246

2023

Volltextzugriff (PDF)

EPH164 Estimation of the Burden of C.Difficile Infection in Community and Hospital Settings in France From 2015-2019: Results From a National Health Insurance Database Study (The CLODICIA SNDS Study)

Value in health, 2022-12, Vol.25 (12), p.S222-S222

2022

Volltextzugriff (PDF)

PCV5 Clinical Characteristics of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in France: EPACT, a Study Based on the French Nationwide Claims Database Snds

Value in health, 2020-12, Vol.23, p.S486-S487

2020

Volltextzugriff (PDF)

PCV67 Epidemiology of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in France: EPACT, a Study Based on the French Nationwide Claims Database Snds

Value in health, 2020-12, Vol.23, p.S498-S499

2020

Volltextzugriff (PDF)

PCV7 Development of an Algorithm Using the Dispensed Daily Doses of LOOP Diuretics to Assess Survival of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) According to the Disease Severity

Value in health, 2020-12, Vol.23, p.S487-S487

2020

Volltextzugriff (PDF)

Identification des patients atteints d’amylose cardiaque à transthyrétine (ATTR-CM) en France : E-PACT, une étude basée sur les données du Système national des données de santé (SNDS)

Revue d'épidémiologie et de santé publique, 2021-06, Vol.69, p.S109-S109

2021

Volltextzugriff (PDF)

What Criteria for Pharmaceuticals Reimbursement?: An Empirical Analysis of the Evaluation of "Medical Service Rendered" by Reimbursable Drugs in France

The European journal of health economics, 2003, Vol.4 (1), p.30-36

2003

Volltextzugriff (PDF)

Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases

Archives of cardiovascular diseases supplements, 2023-01, Vol.15 (1), p.47

2023

Volltextzugriff (PDF)

Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years

European journal of ophthalmology, 2005-09, Vol.15 (5), p.562-580

2005

Volltextzugriff (PDF)

MD2 THE PARAMETRIC BOOTSTRAP: RECONCILING PARAMETRIC AND NON PARAMETRIC METHODS IN THE ESTIMATION OF CONFIDENCE INTERVALS FOR INCREMENTAL COST-EFFECTIVENESS RATIOS?

Value in health, 2003-11, Vol.6 (6), p.610-610

Lilliu, H

2003

Volltextzugriff (PDF)

Estimating the long-term visual field consequences of average daily intraocular pressure and variance : a clinical trial comparing timolol, latanoprost and travoprost

Clinical drug investigation, 2003-01, Vol.23 (7), p.431-438

2003

Volltextzugriff (PDF)

Cost-minimization study comparing simulect versus thymoglobulin in renal transplant induction

Transplantation proceedings, 2001-11, Vol.33 (7), p.3197-3198

2001

Volltextzugriff (PDF)

PND9 HEALTH CARE COSTS STRATIFIED BY EPILEPSY SEVERITY IN A US COMMERCIALLY INSURED SETTING

Value in health, 2010, Vol.13 (3), p.A138-A138

2010

Volltextzugriff (PDF)

Calcium–vitamin D 3 supplementation is cost-effective in hip fractures prevention

Maturitas, 2003-04, Vol.44 (4), p.299-305

2003

Volltextzugriff (PDF)

PES5 COST-UTILITY ANALYSIS OF TIMOLOL VERSUS LATANOPROST VERSUS TRAVOPROST IN THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION

Value in health, 2002-11, Vol.5 (6), p.552-553

2002

Volltextzugriff (PDF)

Cost-minimization study comparing Simulect® vs. Thymoglobulin® in renal transplant induction

Clinical transplantation, 2004-06, Vol.18 (3), p.247-253

2004

Volltextzugriff (PDF)

Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease

Revue neurologique, 2001-05, Vol.157 (5), p.507

2001

Volltextzugriff (PDF)

OA3 HOW DO PRESCRIBERS ACT WHEN A PRODUCT IS WITHDRAWN FROM THE MARKET? FIRST LESSONS FROM THE COX-2 INHIBITORS PATIENTS POST ROFECOXIB STUDY (CIPRES)

Value in health, 2006-11, Vol.9 (6), p.A200-A201

2006

Volltextzugriff (PDF)

CV12 A COST-EFFECTIVENESS ANALYSIS OF ACE INHIBITOR TRANDOLAPRIL AS A PREVENTATIVE TREATMENT OF HEART-FAILURE PROGRESSION

Value in health, 2003-11, Vol.6 (6), p.631-631

2003

Volltextzugriff (PDF)

PAE13 COST-EFFECTIVENESS ANALYSIS OF TIMOLOL LATANOPROST AND TRAVOPROST IN 3 EUROPEAN COUNTRIES: THE UK, GERMANY AND FRANCE

Value in health, 2003-11, Vol.6 (6), p.640-640

2003

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Epidemiology of transthyretin amyloid cardiomyopathy (ATTR-CM) in France, a study based on the systeme national des donnees de sante (SNDS) the French nationwide claims database

HPR122 Cost-Based vs Value-Based - How Do Japan's and Germany's Pricing Frameworks Compare?

HPR161 A Long-Term Forecast of the Economic Impact of Gene Therapies in France

RWD98 Health Care Resource Use and Costs of Hemophilia A in France

EE565 Healthcare Consumption and Costs of Hemophilia B in France

EPH233 Estimation of the Epidemiological and Economic Burden of RSV and Influenza Infection in the Hospital Setting Among Adults 65 Years and Older in France

EPH164 Estimation of the Burden of C.Difficile Infection in Community and Hospital Settings in France From 2015-2019: Results From a National Health Insurance Database Study (The CLODICIA SNDS Study)

PCV5 Clinical Characteristics of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in France: EPACT, a Study Based on the French Nationwide Claims Database Snds

PCV67 Epidemiology of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in France: EPACT, a Study Based on the French Nationwide Claims Database Snds

PCV7 Development of an Algorithm Using the Dispensed Daily Doses of LOOP Diuretics to Assess Survival of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) According to the Disease Severity

Identification des patients atteints d’amylose cardiaque à transthyrétine (ATTR-CM) en France : E-PACT, une étude basée sur les données du Système national des données de santé (SNDS)

What Criteria for Pharmaceuticals Reimbursement?: An Empirical Analysis of the Evaluation of "Medical Service Rendered" by Reimbursable Drugs in France

Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases

Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years

MD2 THE PARAMETRIC BOOTSTRAP: RECONCILING PARAMETRIC AND NON PARAMETRIC METHODS IN THE ESTIMATION OF CONFIDENCE INTERVALS FOR INCREMENTAL COST-EFFECTIVENESS RATIOS?

Estimating the long-term visual field consequences of average daily intraocular pressure and variance : a clinical trial comparing timolol, latanoprost and travoprost

Cost-minimization study comparing simulect versus thymoglobulin in renal transplant induction

PND9 HEALTH CARE COSTS STRATIFIED BY EPILEPSY SEVERITY IN A US COMMERCIALLY INSURED SETTING

Calcium–vitamin D 3 supplementation is cost-effective in hip fractures prevention

PES5 COST-UTILITY ANALYSIS OF TIMOLOL VERSUS LATANOPROST VERSUS TRAVOPROST IN THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION

Cost-minimization study comparing Simulect® vs. Thymoglobulin® in renal transplant induction

Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease

OA3 HOW DO PRESCRIBERS ACT WHEN A PRODUCT IS WITHDRAWN FROM THE MARKET? FIRST LESSONS FROM THE COX-2 INHIBITORS PATIENTS POST ROFECOXIB STUDY (CIPRES)

CV12 A COST-EFFECTIVENESS ANALYSIS OF ACE INHIBITOR TRANDOLAPRIL AS A PREVENTATIVE TREATMENT OF HEART-FAILURE PROGRESSION

PAE13 COST-EFFECTIVENESS ANALYSIS OF TIMOLOL LATANOPROST AND TRAVOPROST IN 3 EUROPEAN COUNTRIES: THE UK, GERMANY AND FRANCE

Suchergebnisse filtern